ArticleClinical rheumatology2025
The VITACORA- 19 and PsAID questionnaires are equally valid for assessing the impact of psoriatic arthritis on patients' quality of life.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsHealth-related quality of life (HRQoL) is an often-underestimated aspect in psoriatic arthritis (PsA). We aimed to compare the VITACORA-19 and PsAID (Psoriatic Arthritis Impact of Disease) questionnaires to assess QoL in routine PsA management.
methodsCross-sectional analysis of a randomly selected PsA population. Disease activity was estimated using the DAPSA (Disease Activity score for PsA) index and HRQoL using the VITACORA-19 and PsAID. The construct validity of VITACORA-19 was analysed (Pearson correlation and ROC curves).
resultsForty-five patients were included, 24 men and 21 women, mean age 55 ± 13 years, mean disease duration 8.2 ± 6.1 years. Most patients showed adequate disease control, median DAPSA 11.3 (IQR: 8.0-19.3), median PsAID 2.7 (IQR: 1.1-5.0). VITACORA-19 scores ranged from 6 to 94. The correlation between VITACORA-19 and PsAID was high, r: -0.7 (95%CI: -0.84 to -0.46), p < 0.0001. A VITACORA-19 score in the range of 6-29 corresponded to high DAPSA disease activity, a range of 30-44 corresponded to moderate DAPSA activity and a range of 45-95 corresponded to low DAPSA activity. The cut-off for an acceptable symptomatic state (PsAID < 4) corresponded to a VITACORA-19 score ≥ 66 with an area under the ROC curve of 0.85 (95%CI: 0.71-0.98).
conclusionsThis is the first study comparing the VITACORA-19 and PsAID questionnaires. Either of the two questionnaires could be used to assess HRQoL in PsA. For the first time, VITACORA-19 thresholds are defined that identify the different DAPSA activity categories. A VITACORA-19 score ≥ 66 could be an appropriate treatment target. Key Points • Health-related quality of life (HRQoL) is an often-underestimated aspect in psoriatic arthritis (PsA). • The PsAID and VITACORA-19 questionnaires offer similar performance for assessing HRQoL in PsA. • A VITACORA-19 ≥ 66 identifies the low disease impact state according to the PsAID. • VITACORA-19 thresholds identifying DAPSA categories are reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.